Lantheus Medical Imaging said the first Phase III trial involving its 18F-flurpiridaz PET agent has cleared a data analysis milestone, and the research will continue. The program comprises two trials involving 1,400 North American and European patients. The agent is being tested in myocardial perfusion imaging of patients believed or known to have coronary artery disease.
Lantheus moves forward with study of 18F-flurpiridaz for MPI
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.